Faculty

Institution

Unit

Venue

Ming Zhao

Associate Professor

The University of Texas MD Anderson Cancer Center

Affiliations

School Of Public Health

School of Health Professions

The University of Texas MD Anderson Cancer Center

Ming Zhao is currently serving as a School Of Public Health Associate Professor at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Ming Zhao

The University of Texas MD Anderson Cancer Center

Associate Professor

You can click a keyword to filter the displayed items

cell biology oncogenes cancer cells cancer research therapeutic targets oncology tumor biology molecular cancer anti-cancer agents cancer biology pathology cancer treatment molecular biology breast cancer reproductive biology developmental biology leukemia molecular cell biology medicinal research breast oncology hematology reproductive science cancer discovery hematological malignancies carcinogenesis tumor targeting novel therapies cellular therapy tumor suppressors molecular and cellular biology cancer letter myeloid neoplasia cancer genetics therapeutic efficacy mammalian biology molecular diagnostics gametogenesis gametes chromatin remodeling epigenetic changes receptor tyrosine kinases biliary cancer transition nuclear proteins situ hybridization anti-tumor efficacy cell metabolism molecular metabolism free radical biology fertilisation cellular biology genome instability nuclear organization chemoprevention strategies metabolic remodeling chromosome biology germ cell fate reproductive physiology cell regulation malignant blood disorders germ cells biomarker discovery immunophenotyping immune checkpoint inhibitors gene affects chromatin structure normal chromatin condensation functional sperm development sperm development tnp2 mutations1 nucleoprotein transitions antitumor efficacy multiple myeloma cyclin d2 expression triple-negative breast cancer preclinical models mouse dead-end gene reproductive endocrinology reproductive medicine bioethics fertility cell division infertility reproductive health assisted reproduction gynecology human biology embryology

Notable Scholarly Works

Notable Federal Grants

Collaborators

Data From Antitumor Activity and Biomarker Analysis for Trop2 Antibody–Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models. (2025)

breast oncologybiomarker analysisradiation oncologytumor targetingdrug targetinganti-cancer agentsmolecular cancercancer discoverypharmacologytherapeutic targetsantitumor activitycancer cellsbreast cancer

Data From Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. (2025)

biostatisticsradiation oncologyoncologymodel precision oncologypatient-derived xenograftsadaptive radiotherapysurgical oncologycancer imagingcancer researchtumor heterogeneitypersonalized medicinebiliary tract cancer

Efficacy of Atr Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors With Dna Damage Response Pathway and Other Genomic Alterations. Molecular Cancer Therapeutics (2025)

oncogenesradiation oncologypathologytumor biologydna repairmolecular medicinecell biologymolecular cancerleukemiacarcinogenesiscancer researchcancer discoveryjama oncologytherapeutic targetscancer cellscancer letteroncology

Supplementary Tables 1 - 8 From Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. (2025)

biostatisticsradiation oncologytumor biologymodel precision oncologypatient-derived xenograftssurgical oncologysupplementary tables 1cancer researchpersonalized medicinecancer treatmentcancer lettercancer managementoncologytumor heterogeneity

Abstract 4536: Mtap Loss Alters the Epigenetic Landscape and Demonstrates Superior Therapeutic Sensitivity to Concomitant Prmt5 and Parp Inhibition in Cholangiocarcinoma. Cancer Research (2024)

Pooja A. ShahAjay Kumar SawWilliam PadronMing ZhaoArgun AkcakanatKurt EvansFunda Meric-BernstamMilind JavleJordi RodonKunal Rai

mtap lossoncogenesgene therapyepigenetic landscapesuperior therapeutic sensitivityparp inhibitionmolecular medicinecancer researchpharmacologymolecular biologytherapeutic targetstherapeutic efficacycancer treatmentcancer geneticsoncologycancer biology

Data From Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in Her2-Expressing Cancers. (2024)

oncogenestumor targetingtumor biologycancer biologyanti-cancer agentsher2-expressing cancerscancer immunotherapycell biologymedicinal researchmolecular cancercancer researchpharmacologytherapeutic targetstrastuzumab deruxtecancancer cellsbreast cancer

Data From Co-Clinical Trial of Novel Bispecific Anti-Her2 Antibody Zanidatamab in Patient-Derived Xenografts. (2024)

future medicinal chemistrydrug targetingapplied pharmacologytranslational medicinemedicinal researchnovel therapiesantibody engineeringdrug resistanceco-clinical trialmedicinepharmacologytherapeutic targetsdrug discoverypharmacotherapypharmacological researchtranslational pharmacologypatient-derived xenografts

Data From Combining Neratinib With Cdk4/6, Mtor, and Mek Inhibitors in Models of Her2-Positive Cancer. (2024)

oncogenestumor biologyher2-positive canceranti-cancer agentscell biologymolecular cancermek inhibitorscancer researchpharmacologytherapeutic targetscancer cellscancer treatmentoncologycancer biology

Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 From Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in Her2-Expressing Cancers. (2024)

Figure S1, Figure S2, Figure S3, Figure S4 From Co-Clinical Trial of Novel Bispecific Anti-Her2 Antibody Zanidatamab in Patient-Derived Xenografts. (2024)

future medicinal chemistrydrug developmentfigure s1applied pharmacologyimmunologymedicinal researchnovel therapiesfigure s2antibody engineeringdrug resistancemedicinepharmacologytherapeutic targetsdrug discoverypharmacotherapyfigure s4

1
2
3
4
5
6
10 / page

Ming Zhao

Associate Professor

The University of Texas MD Anderson Cancer Center

Affiliations

School Of Public Health

School of Health Professions

The University of Texas MD Anderson Cancer Center

Ming Zhao is currently serving as a School Of Public Health Associate Professor at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Ming Zhao

The University of Texas MD Anderson Cancer Center

Associate Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Data From Antitumor Activity and Biomarker Analysis for Trop2 Antibody–Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models. (2025)

Data From Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. (2025)

Efficacy of Atr Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors With Dna Damage Response Pathway and Other Genomic Alterations. Molecular Cancer Therapeutics (2025)

Supplementary Tables 1 - 8 From Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. (2025)

Abstract 4536: Mtap Loss Alters the Epigenetic Landscape and Demonstrates Superior Therapeutic Sensitivity to Concomitant Prmt5 and Parp Inhibition in Cholangiocarcinoma. Cancer Research (2024)

Pooja A. ShahAjay Kumar SawWilliam PadronMing ZhaoArgun AkcakanatKurt EvansFunda Meric-BernstamMilind JavleJordi RodonKunal Rai

Data From Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in Her2-Expressing Cancers. (2024)

Data From Co-Clinical Trial of Novel Bispecific Anti-Her2 Antibody Zanidatamab in Patient-Derived Xenografts. (2024)

Data From Combining Neratinib With Cdk4/6, Mtor, and Mek Inhibitors in Models of Her2-Positive Cancer. (2024)

oncogenestumor biologyher2-positive canceranti-cancer agentscell biologymolecular cancermek inhibitorscancer researchpharmacologytherapeutic targetscancer cellscancer treatmentoncologycancer biology

Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 From Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in Her2-Expressing Cancers. (2024)

Figure S1, Figure S2, Figure S3, Figure S4 From Co-Clinical Trial of Novel Bispecific Anti-Her2 Antibody Zanidatamab in Patient-Derived Xenografts. (2024)

1
2
3
4
5
6
10 / page